Telomerase Promoter - Cancer Therapies

submit enquiry
Telomerase Promoter - Cancer Therapies
Telomerase Promoter - Cancer Therapies

University: University of Glasgow

Sector(s): Healthcare & Pharmaceuticals, Life Sciences

About Opportunity:

Improving suicide-gene therapy for the treatment of cancer.

The University of Glasgow has developed a telomerase targeted adenoviral suicide-gene therapy vector (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.

Suicide-gene therapy aims to selectively target cancer cells without harming normal cells thus reducing the toxicity associated with conventional therapies.

To achieve this selectivity, gene therapy approaches require mechanisms to regulate and limit the expression of therapeutic genes to cancer cells .Achieving this aim remains a challenge for the development of clinically useful suicide gene-therapy.

In-vitro/in-vivo experiments against ovarian cancer cells have confirmed that this construct provides efficient cancer cell kill whilst minimising harmful effects on normal cells.

Key Benefits:

  • In-vitro / In-vivo data demonstrates the benefits of the hTR telomerase gene to effectively regulate the expression of genes to activate cytotoxic compounds in cancer cells and not normal cells.
  • hTR Telomerase regulated pro-drug therapies could provide safe and therapeutically enhanced pro-drug treatments that target cancer cells whilst leaving normal cells unaffected.
  • Ovarian human cancer cell lines showed specific enhancement of the cytotoxic effects of CB1954 on cancer cells with the adenovirus / hTR / NTR construct.

Applications:

Tumour-specific gene promoters can be used for transcriptional targeting to improve selectivity and increase therapeutic index. However until recently this has been difficult as many tumour specific promoters show weak transcriptional activity and are unable to drive efficient expression of the therapeutic gene. In addition, the promoter activity is often restricted to one tumour type for example HER2/NEU positive is limited to use with breast cancer.

IP Status:

This technology is available as an Easy Access deal, available to companies and individuals to license for FREE.

Enquiry

Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Please prove you are a human by completing this simple image recognition task.

Related Opportunities

  • Catanostics - Non-Invasive Early Stage Cataract Diagnosis & Severity Quantification tool

    Catanostics (Cataract Diagnostics) offers an alternative to the slit lamp currently used for cataract diagnosis before referring a patient for cataract surgery. Our non-invasive fluorescence scan offers "better diagnosis" through non-subjective analysis of data on cataract symptoms & severity lea...

    Expires: Created:
  • Transforming Pharmaceutical Crystal Forms

    The innovation provides a gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

    Expires: Created:
  • Visual field testing device for improved patient experience

    Researchers at the University of Edinburgh have developed a visual field testing device that uses a strategy that is more natural for the patient than current gold standard tests resulting in an improved patient experience.

    Expires: Created:
  • Radio Frequency Ablation (RFA)

    Researchers at the University of Dundee have developed a novel “intelligent” RFA device for destroying solid tumours in situ. This new concept in RFA treatment overcomes the limitations of current technology by providing a safe, versatile and highly effective method for complete tumour ablation ther...

    Expires: Created:
  • Sperm Motility Enhancers for Assisted Reproductive Technology

    Sperm Motility Enhancers: A Novel Strategy for Assisted Reproductive Technology (ART) based on the direct relationship between human fertility and sperm motility,the University of Dundee has successfully identified FDA-approved compounds with robust and effective stimulation on patient sperm motilit...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities


Register Now for University Technology.com Alerts


Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.